Complicated Urinary Tract Infections Pipeline Analysis Report 2025
Description
Complicated urinary tract infections (cUTIs) are severe infections affecting the urinary system, often associated with structural abnormalities or underlying health conditions. Globally, UTIs impact over 150 million people annually, with cUTIs accounting for a significant portion due to their complexity and resistance to standard treatments. The rising prevalence of antibiotic-resistant bacteria is driving the demand for more effective therapies. In response, pharmaceutical companies are focusing on the development of advanced antibiotics and complicated urinary tract infections therapeutic products. Recent innovations, such as new drug candidates like Cefiderocol and Fosfomycin, indicate robust growth in the pipeline in the coming years.
Report Coverage
The Complicated Urinary Tract Infections Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into complicated urinary tract infections therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for complicated urinary tract infections. The complicated urinary tract infections report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The complicated urinary tract infections pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with complicated urinary tract infections treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to complicated urinary tract infections.
Complicated Urinary Tract Infections Drug Pipeline Outlook
Complicated urinary tract infections (cUTIs) are severe infections that affect the bladder, kidneys, or urethra. They often arise due to structural abnormalities, the use of urinary catheters, or underlying health conditions such as diabetes. These infections are frequently caused by antibiotic-resistant bacteria, which makes them more challenging to treat and increases the risk of recurrence and complications if not managed properly.
Complicated urinary tract infections treatment involves broad-spectrum antibiotics, which are often administered intravenously in severe cases. Commonly used medications include Carbapenems, Cefiderocol, and Fosfomycin. It is essential to implement personalized therapies based on bacterial culture and sensitivity tests. New drug candidates and innovative treatments are being developed to address antibiotic resistance and enhance patient outcomes. Early diagnosis and targeted treatment are crucial for effective management.
Complicated Urinary Tract Infections Epidemiology
Globally, urinary tract infections (UTIs) affect over 150 million people annually, making them one of the most common bacterial infections. In the United States, complicated UTIs account for over 626,000 hospitals admissions each year, representing approximately 1.8% of all hospitalizations. In the United Kingdom, around half of all women experience a UTI, while in India, UTI prevalence in women ranges from 3.14% to 19.87%, highlighting the significant disease burden.
Complicated Urinary Tract Infections – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of complicated urinary tract infections drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total complicated urinary tract infections clinical trials.
Complicated Urinary Tract Infections – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the complicated urinary tract infections pipeline analysis include small molecules, monoclonal antibodies, peptides, beta-lactamase inhibitors, nanoparticles, others. The complicated urinary tract infections report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for complicated urinary tract infections.
Complicated Urinary Tract Infections Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the complicated urinary tract infections drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed complicated urinary tract infections therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in complicated urinary tract infections clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for complicated urinary tract infections. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of complicated urinary tract infections drug candidates.
Drug: Combination of Imipenem/Cilastatin and XNW4107
Imipenem/Cilastatin/XNW4107, sponsored by Evopoint Biosciences Inc., is currently undergoing a Phase 3 study. This study aims to evaluate the efficacy and safety of the drug compared to meropenem in hospitalized adults with complicated urinary tract infections (cUTIs). XNW4107 (Funobactam) is a novel serine β-lactamase inhibitor that enhances the activity of carbapenems against resistant bacterial strains such as Acinetobacter baumannii and Klebsiella pneumoniae.
Cefepime and Enmetazobactam Combination
Cefepime-enmetazobactam, developed by Allecra, is currently being studied in a Phase 2 trial to assess its pharmacokinetics, safety, and tolerability in pediatric patients with complicated urinary tract infections (cUTIs). This intravenous medication combines cefepime, a fourth-generation cephalosporin, with enmetazobactam, a novel β-lactamase inhibitor that specifically targets ESBL-producing Enterobacterales.
Reasons To Buy This Report
The Complicated Urinary Tract Infections Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for complicated urinary tract infections. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into complicated urinary tract infections collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Complicated Urinary Tract Infections – Pipeline Insight Report
Uncomplicated Urinary Tract Infection Epidemiology Forecast
Global Urinary Catheters Market Report and Forecast
Global Clinical Trials Market
Report Coverage
The Complicated Urinary Tract Infections Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into complicated urinary tract infections therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for complicated urinary tract infections. The complicated urinary tract infections report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The complicated urinary tract infections pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with complicated urinary tract infections treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to complicated urinary tract infections.
Complicated Urinary Tract Infections Drug Pipeline Outlook
Complicated urinary tract infections (cUTIs) are severe infections that affect the bladder, kidneys, or urethra. They often arise due to structural abnormalities, the use of urinary catheters, or underlying health conditions such as diabetes. These infections are frequently caused by antibiotic-resistant bacteria, which makes them more challenging to treat and increases the risk of recurrence and complications if not managed properly.
Complicated urinary tract infections treatment involves broad-spectrum antibiotics, which are often administered intravenously in severe cases. Commonly used medications include Carbapenems, Cefiderocol, and Fosfomycin. It is essential to implement personalized therapies based on bacterial culture and sensitivity tests. New drug candidates and innovative treatments are being developed to address antibiotic resistance and enhance patient outcomes. Early diagnosis and targeted treatment are crucial for effective management.
Complicated Urinary Tract Infections Epidemiology
Globally, urinary tract infections (UTIs) affect over 150 million people annually, making them one of the most common bacterial infections. In the United States, complicated UTIs account for over 626,000 hospitals admissions each year, representing approximately 1.8% of all hospitalizations. In the United Kingdom, around half of all women experience a UTI, while in India, UTI prevalence in women ranges from 3.14% to 19.87%, highlighting the significant disease burden.
Complicated Urinary Tract Infections – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of complicated urinary tract infections drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Beta-Lactamase Inhibitors
- Nanoparticles
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total complicated urinary tract infections clinical trials.
Complicated Urinary Tract Infections – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the complicated urinary tract infections pipeline analysis include small molecules, monoclonal antibodies, peptides, beta-lactamase inhibitors, nanoparticles, others. The complicated urinary tract infections report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for complicated urinary tract infections.
Complicated Urinary Tract Infections Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the complicated urinary tract infections drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed complicated urinary tract infections therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in complicated urinary tract infections clinical trials:
- Allecra
- Jiangsu HengRui Medicine Co., Ltd.
- NeuroRx, Inc.
- Wockhardt Ltd.
- Evopoint Biosciences Inc.
- Spero Therapeutics
- Meiji Seika Pharma Co., Ltd.
- Linical Co., Ltd.
- GlaxoSmithKline
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for complicated urinary tract infections. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of complicated urinary tract infections drug candidates.
Drug: Combination of Imipenem/Cilastatin and XNW4107
Imipenem/Cilastatin/XNW4107, sponsored by Evopoint Biosciences Inc., is currently undergoing a Phase 3 study. This study aims to evaluate the efficacy and safety of the drug compared to meropenem in hospitalized adults with complicated urinary tract infections (cUTIs). XNW4107 (Funobactam) is a novel serine β-lactamase inhibitor that enhances the activity of carbapenems against resistant bacterial strains such as Acinetobacter baumannii and Klebsiella pneumoniae.
Cefepime and Enmetazobactam Combination
Cefepime-enmetazobactam, developed by Allecra, is currently being studied in a Phase 2 trial to assess its pharmacokinetics, safety, and tolerability in pediatric patients with complicated urinary tract infections (cUTIs). This intravenous medication combines cefepime, a fourth-generation cephalosporin, with enmetazobactam, a novel β-lactamase inhibitor that specifically targets ESBL-producing Enterobacterales.
Reasons To Buy This Report
The Complicated Urinary Tract Infections Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for complicated urinary tract infections. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into complicated urinary tract infections collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Complicated Urinary Tract Infections – Pipeline Insight Report
- Which companies/institutions are leading the complicated urinary tract infections drug development?
- What is the efficacy and safety profile of complicated urinary tract infections pipeline drugs?
- Which company is leading the complicated urinary tract infections pipeline development activities?
- What is the current complicated urinary tract infections commercial assessment?
- What are the opportunities and challenges present in the complicated urinary tract infections drug pipeline landscape?
- What is the efficacy and safety profile of complicated urinary tract infections pipeline drugs?
- Which company is conducting major trials for complicated urinary tract infections drugs?
- Which companies/institutions are involved in complicated urinary tract infections collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in complicated urinary tract infections?
Uncomplicated Urinary Tract Infection Epidemiology Forecast
Global Urinary Catheters Market Report and Forecast
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Complicated Urinary Tract Infections
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Complicated Urinary Tract Infections
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Complicated Urinary Tract Infections: Epidemiology Snapshot
- 5.1 Complicated Urinary Tract Infections Incidence by Key Markets
- 5.2 Complicated Urinary Tract Infections – Patients Seeking Treatment in Key Markets
- 6 Complicated Urinary Tract Infections: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Complicated Urinary Tract Infections: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Complicated Urinary Tract Infections, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Complicated Urinary Tract Infections Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Complicated Urinary Tract Infections Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Combination of Imipenem/Cilastatin and XNW4107
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: HRS-8427
- 10.2.3 Other Drugs
- 11 Complicated Urinary Tract Infections Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Meropenem-Vaborbactam
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Cefepime and Enmetazobactam Combination
- 11.2.3 Other Drugs
- 12 Complicated Urinary Tract Infections Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Complicated Urinary Tract Infections Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Complicated Urinary Tract Infections, Key Drug Pipeline Companies
- 14.1 Allecra
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Jiangsu HengRui Medicine Co., Ltd.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 NeuroRx, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Wockhardt Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Evopoint Biosciences Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Spero Therapeutics
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Meiji Seika Pharma Co., Ltd.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Linical Co., Ltd.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 GlaxoSmithKline
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
